{"entity":{"id":"nct07084896","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","aka":[],"tldr":"A phase 1/2 trial of Belantamab mafodotin, Nirogacestat in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.","summary":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM is a phase 1/2 interventional study registered as NCT07084896 by GlaxoSmithKline, with 106 participants enrolled, started 2020-06-08 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Nirogacestat. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07084896","url":"https://clinicaltrials.gov/study/NCT07084896"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["adc","gamma-secretase-inhibitors","kinase-inhibitors"],"targets":[],"drugs":["belantamab-mafodotin","nirogacestat"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07084896","phase":"1/2","setting":"A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 3 - Belantamab Mafodotin and Nirogacestat in Combination","sponsor":"GlaxoSmithKline","started":"2020-06-08","startedType":"actual","yearReported":2026,"enrolled":106,"enrolledBasis":"registry","outcomes":[{"endpoint":"CE Phase: Overall Response Rate (ORR)","primary":true,"unit":"%","arms":[{"name":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat","n":34,"value":29,"note":"95% CI 15.1 to 47.5; Figures from the ClinicalTrials.gov results section (first posted 2026-05-06), not from a publication"},{"name":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W","n":37,"value":38,"note":"95% CI 22.5 to 55.2"}],"source":"https://clinicaltrials.gov/study/NCT07084896?tab=results"},{"endpoint":"CE Phase: Progression-free Survival (PFS)","unit":"months","arms":[{"name":"CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat","n":34,"value":3.5,"note":"95% CI 1.4 to 8.6; Figures from the ClinicalTrials.gov results section (first posted 2026-05-06), not from a publication"},{"name":"CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W","n":37,"value":9.6,"note":"95% CI 4.2 to 20.2"}],"source":"https://clinicaltrials.gov/study/NCT07084896?tab=results"}]},"route":"/trials/nct07084896/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"gamma-secretase-inhibitors","kind":"technology","name":"Gamma-secretase inhibitors","route":"/technologies/gamma-secretase-inhibitors/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"},{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}